JAMA Otolaryngology - Head and Neck Surgery This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Core Biopsy and Extranodal Extension in Surgically Treated HPV-Associated Oropharyngeal Squamous Cell Carcinoma
This cohort study assesses whether preoperative nodal core needle biopsy is associated with presence of extranodal extension in final pathology findings among patients with human papillomavirus (HPV) –associated oropharyngeal squamous cell carcinoma targeted for primary surgical resection. (Source: JAMA Otolaryngology - Head and Neck Surgery)
Source: JAMA Otolaryngology - Head and Neck Surgery - July 11, 2023 Category: ENT & OMF Source Type: research

Key Points for Clinicians About the SEER Oral Cancer Survival Calculator
This Special Communication describes a calculator that is designed to provide patient-specific survival estimates based on the severity of an index cancer as well as the competing risk of death of other comorbid ailments. (Source: JAMA Otolaryngology - Head and Neck Surgery)
Source: JAMA Otolaryngology - Head and Neck Surgery - July 10, 2023 Category: ENT & OMF Source Type: research

Personalized Oral Cancer Survival Calculator to Estimate Risk of Death From Oral Cancer or Other Causes
This decision analytical model study of US adults with oral cancer uses health records linked with Medicare files to model an oral cancer survival calculator accounting for other health-related causes of death. (Source: JAMA Otolaryngology - Head and Neck Surgery)
Source: JAMA Otolaryngology - Head and Neck Surgery - July 10, 2023 Category: ENT & OMF Source Type: research

Novel Oral Cancer Survival Calculator —Do We Have a Crystal Ball?
With a new diagnosis of head and neck cancer, the foremost priority for patients is survival. Naturally, patients wrestle with treatment options, the implications on survival outcomes, and adverse effects. To guide these crucial conversations, in this issue of JAMA Otolaryngology –Head& Neck Surgery, Davies et al present a predictive model for oral cavity squamous cell cancer (OCC) that seeks to provide a “holistic and personalized” estimate of survival that incorporates general health status and competing causes of death. The calculator accounts for patients’ variable and often low literacy of survival curves ...
Source: JAMA Otolaryngology - Head and Neck Surgery - July 10, 2023 Category: ENT & OMF Source Type: research

Oncologic Significance of Therapeutic Delays in Oral Cavity Cancer
This cohort study reports treatment delays for patients with oral cavity cancer in Canada and evaluates the outcome of treatment delays on overall survival. (Source: JAMA Otolaryngology - Head and Neck Surgery)
Source: JAMA Otolaryngology - Head and Neck Surgery - July 9, 2023 Category: ENT & OMF Source Type: research

Treatment Delays in Oral Cavity Cancer
Timeliness and multidisciplinary coordination have long been recognized as 2 hallmarks of quality cancer care. These quality pillars are especially relevant in the treatment of locally advanced head and neck cancer (HNC), which is founded on precise patient-centered coordination of a multiteam system (eg, interdependent teams of surgical, radiation, and medical oncology teams). Recognizing the importance of timely, coordinated multidisciplinary care in improving outcomes and equity in patients with HNC, the American College of Surgeons/Commission on Cancer selected initiation of adjuvant radiation therapy within 6 weeks of...
Source: JAMA Otolaryngology - Head and Neck Surgery - July 9, 2023 Category: ENT & OMF Source Type: research

Performance of Liquid Biopsy for Diagnosis and Surveillance of HPV-Associated Oropharyngeal Cancer
This cohort study aims to establish the clinical efficacy of plasma tumor tissue –modified human papillomavirus DNA testing in the diagnosis and surveillance of human papillomavirus–associated oropharyngeal squamous cell carcinoma in a contemporary clinical setting. (Source: JAMA Otolaryngology - Head and Neck Surgery)
Source: JAMA Otolaryngology - Head and Neck Surgery - July 9, 2023 Category: ENT & OMF Source Type: research

Circulating Human Papillomavirus Tumor DNA —Ready for Prime Time?
The detection of cell-free tumor DNA fragments shed into the circulation, reflecting the mutational landscape of a tumor type, has transformed the management of many cancers but not head and neck cancer. In contrast with other head and neck carcinomas, human papillomavirus (HPV)-associated oropharynx cancer has a unique and pervasive molecular signature that would make it an ideal candidate for detection and surveillance of HPV-mediated disease. Recent advances in the technology have enabled the sensitive and reliable identification and quantification of low copy number HPV gene expression in the blood. The clinical assay ...
Source: JAMA Otolaryngology - Head and Neck Surgery - July 9, 2023 Category: ENT & OMF Source Type: research

Surgery vs Chemoradiation Outcomes in Patients With T1-T2 Oropharyngeal Squamous Cell Carcinoma
This national multicenter cohort study of patients with T1-T2 oropharyngeal squamous cell carcinoma compares the functional and survival outcomes of primary transoral robotic surgery vs primary radiation therapy and/or chemoradiation. (Source: JAMA Otolaryngology - Head and Neck Surgery)
Source: JAMA Otolaryngology - Head and Neck Surgery - July 9, 2023 Category: ENT & OMF Source Type: research

Size Threshold Surveillance —A Revised Approach to Wait-and-Scan for Vestibular Schwannoma
This Viewpoint discusses how recent discoveries surrounding the natural history of sporadic vestibular schwannoma provide data to support a shift in current management paradigms. (Source: JAMA Otolaryngology - Head and Neck Surgery)
Source: JAMA Otolaryngology - Head and Neck Surgery - July 6, 2023 Category: ENT & OMF Source Type: research

Fears in Patients With Low-Risk Papillary Thyroid Cancer
This cohort study explores the association between gender and fears of low-risk papillary thyroid cancer disease progression, as well as its potential surgical treatment. (Source: JAMA Otolaryngology - Head and Neck Surgery)
Source: JAMA Otolaryngology - Head and Neck Surgery - July 6, 2023 Category: ENT & OMF Source Type: research

Complex Lymphatic Drainage in Head and Neck Cutaneous Melanoma and SLNB Outcomes —Reply
In Reply We thank Drs Adigbli, Woolley, and Issa for their interest in our work and welcome the opportunity to clarify some of the queries raised. (Source: JAMA Otolaryngology - Head and Neck Surgery)
Source: JAMA Otolaryngology - Head and Neck Surgery - July 6, 2023 Category: ENT & OMF Source Type: research

Population-Based Genomic RET Screening —Reply
In Reply We are thankful for the opportunity to reply to the points raised by Machens and Dralle on our commentary on the study by Pichardo et al. As correctly pointed out, thanks to the contributions of Machens and Dralle and their group, much is now known about the progression of disease from no medullary thyroid cancer (MTC) to node-negative MTC to node-positive MTC. We agree with the authors that prophylactic thyroidectomy is an effective means of intervening and removing the thyroid gland when MTC is confined to the gland. However, more data are needed to understand when is the optimal time for a patient to be subject...
Source: JAMA Otolaryngology - Head and Neck Surgery - July 6, 2023 Category: ENT & OMF Source Type: research

Shared Decision-making Among Clinicians and Patients With Low-risk Differentiated Thyroid Cancer —Reply
In Reply We thank Drs Nkhalamba, Hampton, and Mulwafu for their interest in our article. (Source: JAMA Otolaryngology - Head and Neck Surgery)
Source: JAMA Otolaryngology - Head and Neck Surgery - July 6, 2023 Category: ENT & OMF Source Type: research

Complex Lymphatic Drainage in Head and Neck Cutaneous Melanoma and SLNB Outcomes
To the Editor We read with interest the article by Pasha et al, addressing an important topic in melanoma investigation. The authors found that head and neck melanoma had the highest rate of regional recurrences (16.0% vs 9.5% trunk and 8.2% limb, median follow-up 4.8 years). However, the presented percentages represent the average number of regional recurrences per patient with negative sentinel lymph node biopsy (SLNB) status, calculated as the number of regional recurrences in patients with SLNB-negative status divided by the number of patients with false-negative (FN) results. This differs from recurrence rates in FN r...
Source: JAMA Otolaryngology - Head and Neck Surgery - July 6, 2023 Category: ENT & OMF Source Type: research